The revised price rates are as follows:Remdesivir is considered a key anti-viral drug in the fight against COVID-19, especially in adult patients with severe complications.Seven Indian companies are producing Injection Remdesivir under voluntary licensing agreement with M/s.
Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month.In a statement on Wednesday, Union Minister Mansukh Mandaviya informed that the current total installed capacity of the seven manufacturers of Remdesivir is 38.80 lakh vials per month.Fast-track approval has been given for seven additional sites having the production capacity of 10 lakh vials per month to six manufacturers.